LRI Investments LLC Acquires 361 Shares of IQVIA Holdings Inc. $IQV

LRI Investments LLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,071 shares of the medical research company’s stock after buying an additional 361 shares during the quarter. LRI Investments LLC’s holdings in IQVIA were worth $3,793,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the business. Canada Pension Plan Investment Board grew its position in IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after acquiring an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of IQVIA by 26.8% in the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after purchasing an additional 304,258 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after acquiring an additional 40,699 shares in the last quarter. Finally, Pacer Advisors Inc. grew its stake in IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after acquiring an additional 854,732 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of IQV stock opened at $198.35 on Friday. The stock’s 50-day moving average is $189.02 and its 200 day moving average is $168.19. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.34. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $33.72 billion, a P/E ratio of 28.70, a PEG ratio of 2.18 and a beta of 1.32.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the firm posted $2.64 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Redburn Partners set a $214.00 price objective on IQVIA in a research note on Wednesday, September 3rd. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Cowen restated a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Finally, Barclays increased their target price on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $236.45.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.